The pharma R&D pipeline expanded by more than 8% last year to reached 20,109 drugs at the start of January, but new additions of COVID-related agents during the past twelve months cannot be said to account for the big increase.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?